

Gastrointestinal, Hepatobiliary, and Pancreatic Pathology

# A Serrated Colorectal Cancer Pathway Predominates over the Classic WNT Pathway in Patients with Hyperplastic Polyposis Syndrome

Karam S. Boparai,\* Evelien Dekker,\*  
Mirjam M. Polak,† Alex R. Musler,†  
Susanne van Eeden,† and Carel J.M. van Noesel†

From the Departments of Gastroenterology and Hepatology,\*  
and Pathology,† Academic Medical Center, Amsterdam,  
the Netherlands

**Hyperplastic polyposis syndrome (HPS) is characterized by the presence of multiple colorectal serrated polyps and is associated with an increased colorectal cancer (CRC) risk. The mixture of distinct precursor lesion types and malignancies in HPS provides a unique model to study the canonical pathway and a proposed serrated CRC pathway in humans. To establish which CRC pathways play a role in HPS and to obtain new support for the serrated CRC pathway, we assessed the molecular characteristics of polyps ( $n = 84$ ) and CRCs ( $n = 19$ ) in 17 patients with HPS versus control groups of various sporadic polyps ( $n = 59$ ) and sporadic microsatellite-stable CRCs ( $n = 16$ ). In HPS and sporadic polyps, *APC* mutations were exclusively identified in adenomas, whereas *BRAF* mutations were confined to serrated polyps. Six of 19 HPS CRCs (32%) were identified in a serrated polyp. Mutation analysis performed in the CRC and the serrated component of these lesions showed identical *BRAF* mutations. One HPS CRC was located in an adenoma, both components harboring an identical *APC* mutation. Overall, 10 of 19 HPS CRCs (53%) carried a *BRAF* mutation versus none in control group CRCs ( $P = 0.001$ ). Six *BRAF*-mutated HPS CRCs (60%) were microsatellite unstable owing to *MLH1* methylation. These findings provide novel supporting evidence for the existence of a predominant serrated CRC pathway in HPS, generating microsatellite-stable and microsatellite-unstable CRCs. (Am J Pathol 2011, 178: 2700–2707; DOI: 10.1016/j.ajpath.2011.02.023)**

Colorectal cancer (CRC) ranks as the second most common cause of cancer-related death in the Western world.<sup>1</sup> The classic model that describes CRC develop-

ment is the adenoma-carcinoma sequence associated with activation of the WNT signaling pathway.<sup>2,3</sup> This pathway is characterized by an initial bi-allelic inactivation of the adenomatous polyposis coli gene (*APC*) followed by mutations in key oncogenes and tumor suppressor genes, including *KRAS*, *DCC*, and *TP53*, resulting in adenoma initiation and progression to CRC. This multistep process of carcinogenesis has been elaborately studied, and much information has been derived from the familial adenomatous polyposis and *MUTYH*-associated polyposis syndromes.

In addition to the adenoma-carcinoma sequence, an alternative, microsatellite-instability (MSI) pathway exists that is characterized by deletion or inactivation of mismatch repair (MMR) genes. Loss of one of the MMR genes occurs in 10% to 15% of sporadic CRCs, whereas 1% to 2% of CRCs with MMR gene loss are due to a hereditary predisposition, ie, in patients with Lynch syndrome carrying a mono-allelic MMR gene defect in the germline.

Recently, a “serrated neoplasia pathway” has been proposed that involves the progression of serrated polyps, ie, hyperplastic polyps (HPs), sessile serrated adenomas (SSAs), and/or traditional serrated adenomas (TSAs), to CRC. The early genetic events of this route, as currently identified, are *BRAF* or *KRAS* mutations and an enhanced CPG island methylation status of multiple genes.<sup>4–11</sup> There is evidence to suggest that a proportion of sporadic MSI CRCs originate from serrated polyps because these lesions commonly harbor hypermethylated *MLH1* combined with *BRAF* mutations.<sup>12–16</sup> In addition, clinico-histologic studies supporting a serrated CRC pathway include CRCs in close vicinity to large HPs,<sup>17,18</sup> CRCs identified in mixed hyperplastic and adenomatous polyps,<sup>19</sup> and increased incidence of serrated polyps in patients with sporadic microsatellite-unstable

Accepted for publication February 22, 2011.

Supplemental material for this article can be found at <http://ajp.amjpathol.org> or at doi: 10.1016/j.ajpath.2011.02.023.

Address reprint requests to Carel J.M. van Noesel, M.D., Ph.D., Professor in Molecular Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. E-mail: [c.j.vannoesel@amc.uva.nl](mailto:c.j.vannoesel@amc.uva.nl).

CRCs.<sup>4,10,20</sup> Currently, however, proof of the existence of a serrated CRC pathway, demonstrated by the combined histologic findings of a serrated polyp directly adjacent to a CRC and concurrent molecular evidence of a sequential relationship, has not been delivered.

Hyperplastic polyposis syndrome (HPS) is a condition characterized by the presence of multiple colorectal serrated polyps. The genetic cause(s) of HPS is largely unknown. We recently demonstrated that HPS can occur in the context of *MUTYH*-associated polyposis,<sup>21</sup> but *MUTYH* mutations seem to occur in only a small proportion of patients with HPS.<sup>22</sup> HPS is associated with an increased CRC risk.<sup>5,7,19,22–27</sup> Previously published case series report CRC at clinical presentation in up to 50% of patients with HPS and interval carcinomas, ie, carcinomas occurring after HPS diagnosis and during endoscopic surveillance, in up to 25% of patients.<sup>24,28</sup> However, because HPS is a heterogeneous condition, comprising serrated polyps of different categories, (ie, HPs and SSAs but also coexistent conventional adenomas<sup>22,23,28–30</sup>) it is uncertain which polyps eventually lead to CRC in these patients and, thus, are clinically relevant. When the CRCs originate from the serrated polyps, HPS may prove to be a valuable model for studying the serrated CRC pathway.

In a cohort of 56 patients with HPS, we identified 17 patients with CRC. By combined histopathologic and molecular analyses of the polyps and CRCs in these patients, we obtained novel evidence of a serrated CRC pathway in HPS that predominates over the classic WNT pathway of carcinogenesis.

## Materials and Methods

### Patients

In a cohort of 56 patients with HPS undergoing endoscopic treatment and surveillance at the Academic Medical Center (Amsterdam, the Netherlands), 21 patients with HPS had CRC. Tissue samples ( $n = 19$ ) from 17 of these patients were included in this study. HPS was defined as at least five histologically diagnosed HPs and/or SSAs proximal to the sigmoid colon, of which two were  $>10$  mm in diameter, or  $>20$  HPs and/or SSAs distributed throughout the colon.<sup>28</sup> Because HPs and SSAs are common findings in HPS and have been shown to be difficult to differentiate microscopically, all serrated polyps were included in the criteria.<sup>31–34</sup> Patients with a known germline *APC* mutation or a bi-allelic *MUTYH* mutation were excluded from the study. The study was conducted in accordance with the research code of the institutional medical ethical committee on human experimentation of the Academic Medical Center and in agreement with the Helsinki Declaration of 1975 as revised in 1983.

### Specimens

All retrieved CRCs ( $n = 19$ ) were formalin-fixed, paraffin-embedded. H&E-stained tissue sections were reevaluated by two pathologists (S.v.E. and C.J.M.v.N.). In addition, all CRCs were reevaluated for the presence of an

adjacent serrated component and for features of a serrated adenocarcinoma as claimed by other researchers.<sup>10</sup> A control group was selected consisting of sporadic microsatellite-stable (MSS) CRCs ( $n = 14$ ) from patients without polyposis matched for age, sex, and CRC location. These CRCs were reevaluated as described previously herein.

In the case of a mutation identified in a CRC,  $\geq 5$  polyps in the closest proximity of the CRC were selected and reviewed by a single pathologist (C.J.M.v.N.) who was blinded to patient characteristics and original histologic diagnosis. Polyps were classified as HP, SSA, TSA, mixed polyp, or conventional adenoma based on the histologic features on H&E staining.<sup>35–37</sup> Polyps with serrated morphologic features, ie, HPs, SSAs, TSAs, and mixed polyps, were collectively designated as “serrated polyps.” A polyp control group consisting of sporadic HPs ( $n = 24$ ), SSAs ( $n = 18$ ), and conventional adenomas ( $n = 17$ ) was also selected from patients without polyposis. For this analysis, lesions from the cecum, ascending colon, transverse colon, and descending colon were regarded as proximal and those from the sigmoid colon and rectum were regarded as distal.

### Somatic Mutation Analysis

Epithelial cells from polyps and CRCs were microdissected, and DNA was isolated as described previously.<sup>38,39</sup> Using previously described primers and assays, DNA was analyzed for mutations in the *APC*-mutation cluster region (*APC*-MCR), *KRAS* (exon 2), *BRAF* (exon 15), and *NRAS* (exons 1 and 2).<sup>38,39</sup> In the case of a CRC in a polyp, mutation analysis of *TP53* (exons 4 to 10) was performed in an attempt to assess whether these two components were clonally related. In the case of an identified genetic mutation in a CRC, mutation analysis of surrounding polyps ( $\geq 5$ ) was performed as described previously herein. Detected mutations were confirmed in a second independent experiment.

### MSI Analysis

The microsatellite status of the CRCs of patients with HPS was determined using an international standard panel of five microsatellite markers (D17S250, D2S123, D5S346, BAT25, and BAT26) using standard techniques. A high degree of MSI (MSI-high) was defined as 2 (40%) unstable markers, MSI-low as one unstable marker, and MSS as no unstable markers.

### IHC Analysis

Immunohistochemical (IHC) analysis was performed on CRCs and polyps of patients with HPS. Unstained 5- $\mu$ m sections were cut from paraffin blocks, and the slides were deparaffinized. The primary monoclonal antibodies used were specific for MLH1 (1:50; BD Pharmingen, San Diego, CA); MSH2 (1:100; Oncogene Research Products, San Diego, CA); MSH6 (1:200; BD Transduction Laboratories, San Jose, CA); PMS2 (1:250; BD Transduction Laboratories); SMAD4 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA); CTNNB1 (1:10,000; BD Biosciences, San Diego, CA), and

TP53 (1:2000; Neomarkers Inc., Fremont, CA). Slides were immersed in 0.3% hydrogen peroxide in methanol for 20 minutes. Subsequently, antigen retrieval was performed by 10 minutes of boiling in a solution of 10 mmol/L Tris and 1 mmol/L EDTA (pH 9) followed by incubation with the previously mentioned diluted primary antibodies during 1 hour at room temperature. Postantibody blocking (ImmunoLogic, Duiven, the Netherlands) in PBS was performed, followed by implementation of an antipolyvalent horseradish peroxidase detection system (ImmunoLogic) to visualize antibody binding sites with 3,3'-diaminobenzidine as a chromogen. Sections were counterstained with hematoxylin.

Immunoreactivity for CTNNB1 ( $\beta$ -catenin) was regarded as positive when strong nuclear staining was observed in >25% of the cells. Stains for TP53 were regarded to be indicative of TP53 dysfunction or deletion when >75% of the lesional nuclei were strongly positive or completely negative (absent staining). Stains for SMAD4, MLH1, MSH2, MSH6, and PMS2 were considered negative when there was complete absence of nuclear expression in all lesional cells. Negative staining in a part of a lesion or in a single crypt was registered separately.

### Statistics

Statistical analyses were performed using a statistical software package (SPSS 12.0.2; SPSS Inc., Chicago, IL). Somatic mutations in CRCs and polyps of patients with HPS were compared with those of a control panel using a two-sided Fisher's exact test. A *P* value of <0.05 was considered statistically significant.

## Results

### Patients

The clinicopathologic features of patients with HPS are summarized in Table 1. The median age of this cohort of

17 patients with HPS at CRC diagnosis was 58 years (range, 41 to 75 years), with a male/female ratio of 8:9. In all the patients, germline *APC* and *MUTYH* mutation analyses were previously performed and were found to be negative. Surgical colonic resection was performed in 14 of these 17 patients (82%): 6 subtotal colectomies, 4 hemicolectomies (2 right sided), and 4 rectosigmoidal resections. Histologic evaluation of biopsy samples and surgical resection specimens from these patients revealed a median of 16 HPs, 7 SSAs, and 2 conventional adenomas per patient. All the patients fulfilled the criteria for HPS defined by the World Health Organization.<sup>30</sup>

### Mutation Analysis in HPS Polyps and Control Group Polyps

A total of 84 polyps, originating from 17 patients with HPS and CRC, were analyzed for pathogenic mutations in the *APC*-MCR, *KRAS* (codons 12 and 13), *BRAF* (codon 600), and *NRAS* (exons 1 and 2). The 84 HPS polyps consisted of 21 HPs, 38 SSAs, 3 TSAs, and 2 mixed polyps (64 serrated polyps) and 20 conventional adenomas. The control group of sporadic lesions (*n* = 59) consisted of 24 HPs and 18 SSAs (42 serrated polyps) and 17 conventional adenomas (Table 2).

Molecular analysis of the HPS polyps and control group polyps showed *APC*-MCR mutations exclusively in the conventional adenomas and *BRAF* mutations exclusively in the serrated polyps: *BRAF* mutations were detected in 48 of 64 HPS serrated polyps (75%), whereas 20 of 42 control group serrated polyps (48%) harbored a *BRAF* mutation (*P* = 0.007). Also, when evaluating patients with HPS individually, each patient harbored predominantly *BRAF* mutations in their serrated polyps. In four patients, besides *BRAF* mutations, a single *KRAS* mutation was identified in a distal serrated polyp. No significant difference in frequency of *KRAS* mutations in serrated polyps was seen between groups (6% versus

**Table 1.** Clinicopathologic Features of Patients with HPS and CRC

Case no.	Age (years)	Sex	CRC location	CRC size (mm) (TNM)	Adjacent polyps
1	59	F	Cecum	56 (T3N0M0)	None
2	41	F	Rectosigmoid	25 (T2N0M0)	None
3	75	M	AC	50 (T3N0M0)	None
4	58	M	Rectosigmoid	4 (TisN0M0)	HP
5	59	M	AC	<20 (T1N0M0)	SSA
6	68	F	AC	95 (T3N0M0)	None
7	43	F	DC	40 (T4N1M0)	None
8	49	F	DC	Not stated (TisN0M0)	HP
9	54	M	DC	50 (T3N0M0)	None
9	54	M	Rectosigmoid	20 (T1N0M0)	None
10	54	F	AC	16 (T1N0M0)	SSA
11	56	F	Rectosigmoid	65 (T2N0M0)	Adenoma
12	61	F	Rectosigmoid	20 (T1N0M0)	None
13	52	M	Rectosigmoid	40 (T3N1M0)	None
14	66	M	AC	8 (T1N0M0)	SSA
15	63	M	AC	6 (T1N0M0)	SSA
16	69	M	TC	120 (T3N1M1)	None
17	68	F	AC	12 (TisN0M0)	None
17	68	F	Rectosigmoid	29 (T2N0M0)	None

F, female; M, male; AC, ascending colon; DC, descending colon; TC, transverse colon; HP, hyperplastic polyps; SSA, sessile serrated adenomas.

**Table 2.** Detected *APC*, *KRAS*, and *BRAF* Mutations in Serrated Polyps (HPS, SSAs, TSAs, and Mixed Polyps) and Adenomas (ADs) of Patients with HPS Compared with a Control Group

Somatic mutation	Patients with HPS, No. (%)		Control group, No. (%)		P value
	Serrated polyps (n = 64)	AD (n = 20)	Serrated polyps (n = 42)	AD (n = 17)	
<i>APC</i>	0	9 (45)	0	7 (41)	NS
<i>BRAF</i>	48 (75)	0	20 (48)	0	0.007*
<i>KRAS</i>	4 (6)	0	7 (17)	4 (24)	0.029†

NS, not significant.

\*Statistically significant P value for *BRAF* mutation frequency in serrated polyps of patients with HPS compared with the frequency in serrated polyps of the control group.

†Statistically significant P value for *KRAS* mutation frequency in ADs of patients with HPS compared with the frequency in ADs of the control group.

17%;  $P = 0.1$ ), but in conventional adenomas of patients with HPS, no *KRAS* mutations were detected compared with 4 of 17 conventional adenomas (24%) in the control group ( $P = 0.029$ ). In none of the polyps were *KRAS* and *BRAF* mutations found together.

When location in the colon was analyzed, no association was seen between the presence of a *BRAF* mutation and polyp location in the HPS and control groups (Table 3). *BRAF* mutations were observed in 36 of 46 proximal HPS serrated polyps (78%) and in 12 of 18 distal HPS serrated polyps (67%). In HPS, *KRAS*-mutated serrated polyps [4 of 18 (22%)] were exclusively detected in the distal colon ( $P = 0.005$ ).

### IHC Analysis in Polyps

In none of the 84 HPS polyps, loss of expression of the MMR genes (*MLH1*, *MSH2*, *MSH6*, and *PMS2*) or *SMAD4* was observed (data not shown). In addition, none of these polyps showed abnormal TP53 staining (either strong nuclear TP53 staining or complete TP53 loss; data not shown). In nine conventional HPS adenomas, we detected strong nuclear CTNNB1 staining (ie, in >25% of lesional cells; data not shown). In five of these adenomas, an *APC*-MCR mutation was identified. In four other *APC*-MCR-mutated adenomas, no abnormal nuclear CTNNB1 staining was detected. Nuclear CTNNB1 was not found in any of the serrated polyps of either group.

### Histologic Characteristics of the CRCs

On histologic reevaluation of CRCs, 6 of 19 HPS CRCs (32%) were identified in or directly adjacent to a serrated polyp. In 1 of 19 cases (5%), the HPS CRC was identified

in a conventional adenoma (Figure 1). One patient had two synchronous CRCs. Although six CRCs were identified in serrated polyps, no HPS CRCs displayed distinguishing morphologic features justifying the diagnosis of serrated adenocarcinoma.<sup>10</sup>

### Mutation Analysis in HPS CRCs and Control Group CRCs

*BRAF* mutations were detected in 10 of 19 HPS CRCs (53%), whereas no *BRAF* mutations were detected in the CRCs of the control group ( $P = 0.001$ ; Table 4 and Figure 2). All *BRAF* mutations involved the same thymine to adenine transversion at nucleotide 1796, resulting in a valine to glutamine substitution at codon 600 (V600E). We found no *NRAS* mutations in the CRCs of either group. Of the six CRCs identified in a serrated polyp, five (83%) carried the same *BRAF* mutation (GTG→GAG) in the polypous and tumor components (Table 5). However, considering that these are hotspot mutations, these findings do not prove a clonal relationship between these lesions. *TP53* (exons 4 to 10) sequence analysis performed on these six CRCs, to further explore the clonal relationship between the carcinomas and precursor lesions, yielded no mutations.

*APC*-MCR mutations were identified in 2 of 19 HPS CRCs (11%) compared with in 4 of 14 CRCs in the control group (29%) (not significant), and 1 of 19 *KRAS* mutations (5%) were detected in HPS CRCs compared with 5 (36%) in the control group (not significant). In one HPS CRC (patient 6), a *BRAF* mutation and an *APC*-MCR mutation were detected. One of the HPS CRCs (patient 11), harboring an *APC*-MCR mutation (insertion 1364), was the single HPS CRC found in a villous adenoma (Figure 1C). Subsequent *APC*-MCR sequence analysis of the ade-

**Table 3.** Serrated Polyp Location and *BRAF* and *KRAS* Mutations

Polyp	<i>BRAF</i> mutation (%)				<i>KRAS</i> mutation (%)			
	HPS group		Control group		HPS group		Control group	
	Proximal	Distal	Proximal	Distal	Proximal	Distal	Proximal	Distal
HP	8/13 (62)	5/8 (63)	1/2 (50)	9/22 (41)	0/13	3/8 (38)	0/2	5/22 (23)
SSA	25/30 (83)	5/8 (63)	10/18 (56)	0/1	0/30	1/8 (13)	2/17 (12)	0/1
TSA	1/1 (100)	2/2 (100)	0/0	0/0	0/1	0/2	0/0	0/0
MP	2/2 (100)	0/0	0/0	0/0	0/2	0/0	0/0	0/0

All values are expressed as number/total number (percentage).

HP, hyperplastic polyps; SSA, sessile serrated adenomas; TSA, traditional serrated adenomas; MP, mixed polyp.



**Figure 1.** Three CRCs of three HPS patients; two CRCs located within two serrated polyps (A and B), and one CRC within a villous adenoma (C). Original magnification,  $\times 50$ .

noma revealed the same mutation (insertion 1364), establishing a clonal relationship between these lesions. Accordingly, both the adenomatous and malignant components displayed evident nuclear CTNNB1 staining (Figure 3).

When location in the colon was analyzed, all *BRAF*-mutated HPS CRCs were exclusively detected in the proximal colon ( $P = 0.007$ ). No association was seen between location and *KRAS* mutations in the control group or *APC* mutations in both groups. The entire list of molecular analyses on a per-carcinoma basis can be found in Supplemental Table S1 (available at <http://ajp.amjpathol.org>).

#### Genetic Events Detected by IHC and Microsatellite Analyses in CRCs

In 6 of 19 HPS CRCs (32%), there was complete loss of expression of MLH1 and PMS2. All six of these HPS CRCs were MSI-high, were proximally located, and harbored a *BRAF* mutation. Two of the six MSI-high CRCs involved combined serrated polyp–CRC lesions. In these lesions, the serrated polyp components were MSS.

Strong nuclear CTNNB1 staining ( $>25\%$ ) was observed in 5 of 19 HPS CRCs (26%). In one of these CRCs, an *APC*-MCR mutation was identified, and none of these was *BRAF* mutated. In all five of these HPS CRCs, abnormal TP53 staining was observed ( $>75\%$  nuclear staining or complete absence), indicative of loss of functional TP53. Three additional HPS CRCs displayed a perturbed TP53 status. In 2 of 19 CRCs (11%), loss of SMAD4, either focal or complete, was detected.

**Table 4.** Mutation Spectrum of CRCs in Patients with HPS Compared with Control Group CRCs

Mutation	HPS carcinomas (n = 19)	Control group carcinomas (n = 14)	P value
<i>APC</i>	2 (11)	4 (29)	NS
<i>KRAS</i>	1 (5)	5 (36)	NS
<i>BRAF</i>	10 (53)	0	0.001*
<i>NRAS</i>	0	0	NS
MSS	12 (63)	14 (100)	NA
MSI-low	1 (5)	0	NA
MSI-high	6 (32)	0	NA


All values are expressed as number (percentage).  
 NS, not significant; NA, not applicable.

\*Statistically significant compared with the control group CRC.

#### Discussion

In this first comprehensive cohort study of patients with HPS and CRCs and polyps, we demonstrated that the serrated polyps and conventional adenomas of patients with HPS not only morphologically resemble their respective sporadic counterparts but also have similar molecular profiles (Table 3 and Figure 2). We identified five combined serrated polyp–CRC lesions that showed identical *BRAF* mutations in both components, supporting the existence of a serrated CRC pathway. Overall, we demonstrated that MSS and MSI CRCs in HPS predominantly originate from the serrated polyps, thus confirming that patients with HPS provide a valuable model to analyze the molecular characteristics of the serrated CRC pathway.

In accord with previous studies,<sup>13,40,41</sup> the HPS serrated polyps harbored significantly more *BRAF* mutations than did those of the control group (75% versus 48%;  $P = 0.007$ ). The slight difference in the *KRAS* mutation frequencies between both groups (7% versus 17%) was not statistically significant. Thus, *BRAF* mutations correlate even stronger with serrated polyps in patients with HPS than in patients without HPS. This contrasts with serrated polyps in patients with *MUTYH*-associated polyposis and



**Figure 2.** Mutation profiles of HPS polyps/CRCs compared with sporadic control group polyps/CRCs. White bars indicate *APC*; gray bars, *KRAS*; black bars, *BRAF*. SPs, serrated polyps; Ads, conventional adenomas.

**Table 5.** Mutations in CRCs and Adjacent Polyps

Carcinoma	Adjacent polyp	Mutation in CRC	Mutation in adjacent polyp
4	HP	None	None
5	SSA	<i>BRAF</i> (GTG→GAG)	<i>BRAF</i> (GTG→GAG)
8	HP	<i>BRAF</i> (GTG→GAG)	<i>BRAF</i> (GTG→GAG)
10	SSA	<i>BRAF</i> (GTG→GAG)	<i>BRAF</i> (GTG→GAG)
11	Adenoma	<i>APC</i> (insertion G 1354)	<i>APC</i> (insertion G 1354)
15	SSA	<i>BRAF</i> (GTG→GAG)	<i>BRAF</i> (GTG→GAG)
16	SSA	<i>BRAF</i> (GTG→GAG)	<i>BRAF</i> (GTG→GAG)


a germline *MUTYH* gene mutation, which contain significantly more *KRAS* mutations (70%) than *BRAF* mutations (4%).<sup>21</sup> *BRAF* and *KRAS* have been identified as early or instigating events in the serrated pathway. It has to be determined, however, whether serrated lesions with these mutually exclusive mutations are biologically equivalent and have the same risk of developing into CRC.

The mutation profiles of the HPS CRCs were clearly more similar to those found in the serrated polyps than in the conventional adenomas (Table 3 and Figure 2). The profiles of the control group MSS CRCs, as expected, were comparable with the profiles of the conventional adenomas. As many as 10 of the included 19 HPS CRCs were *BRAF* mutated compared with none of the 14 control group CRCs ( $P = 0.001$ ). All these *BRAF*-mutated CRCs were proximally located. Previous molecular studies in HPS CRCs encompassed small noncontrolled series of selected cases,<sup>23,42–44</sup> and a comparison between the present results and these studies is not straightforward owing to variation in patient selection criteria and analysis of different or single genes. Overall, however, *BRAF* mutations were identified in 6 of 15 HPS-related CRC cases (40%) described in the literature until now. We identified no *BRAF* mutations in the control group of age- and sex-matched MSS CRCs from patients without polyposis. Concordantly, *BRAF* mutations have been reported in only 5% to 10% of sporadic MSS CRCs of patients without polyposis ( $n > 100$ ).<sup>45–48</sup> Considering that in the literature serrated polyps are suggested to be precursor lesions particularly of MSI CRCs, we chose MSS carcinomas in the control group to exclude MSI CRCs from patients potentially with unrecognized HPS. However, this strategy is arbitrary and eliminates sporadic MSI CRCs from patients without HPS. Hence, the statistically significant difference in *BRAF* mutation frequency between HPS CRCs and control group CRCs is higher compared with that in an unselected cohort of CRCs. We detected only one *KRAS* mutation in a distally located HPS CRC, which corroborates two previously published studies together analyzing 15 HPS CRCs.<sup>40,41</sup> To our knowledge, only one other study has described the presence of a *KRAS* mutation in a single distally located HPS CRC, supporting the notion that *KRAS* plays a minor role

in the carcinogenesis of HPS and is confined to the distal colon.<sup>23</sup>

In the present study, two patients had synchronous CRCs. Theoretically, a field effect may account for the development of synchronous polyps/CRCs.<sup>49</sup> In patient 9, no mutations were identified in both CRCs. Patient 17 harbored one *KRAS* mutation and one *BRAF* mutation in each of the CRCs. Hence, although a field effect associated with a serrated CRC pathway may cause simultaneous CRCs with identical mutations, we did not demonstrate this in patient 9 owing to the lack of any mutations, and it seems excluded in patient 17. Of note, clonal markers are necessary to demonstrate a true field effect. Such clonal markers associated with the serrated pathway are currently not available.

The histologic characteristics of the HPS CRCs as a group, either *BRAF* mutated or not, were inconspicuous and not obviously different from those of control group CRCs. In particular, a serrated growth pattern, as has been reported,<sup>50,51</sup> was not apparent in the present series of HPS CRCs. We found a remarkable number of HPS CRCs [6 of 19 (32%)] to be located in or directly adjacent to a serrated polyp (Figure 1). In five of six of these combined lesions, an identical hotspot mutation at codon 600 (GTG→GAG) of *BRAF* was detected in both components. These combined histologic and molecular data are strongly suggestive of a sequential relationship between serrated polyps and CRCs. A clonal relationship between the carcinomas and their assumed precursor lesions



**Figure 3.** Nuclear CTNNB1 expression in the adenocarcinoma (top) and the adjacent adenoma (bottom) of patient 11, both harboring the same *APC* gene mutation. Original magnification,  $\times 200$ .

could not be further substantiated owing to a lack of appropriate clonal markers.

In the literature, it has been shown that 90% of sporadic MSI-high CRCs display loss of *MLH1* expression as a result of methylation of this MMR gene. In these lesions, *BRAF* mutations, which are associated with serrated polyps, are also a common finding, suggesting that the serrated pathway can generate MSI-high CRCs.<sup>13,15</sup> Six of 19 HPS CRCs were MSI-high owing to loss of *MLH1* and *PMS2*, and all 6 carried *BRAF* mutations. Additional analysis in these CRCs also showed hypermethylation of *MLH1* in all cases (data not shown). These findings suggest a causal relationship between this novel carcinogenic route and microsatellite-unstable CRCs. On the other hand, the present findings demonstrate that the serrated pathway, at least in HPS, also generates MSS CRCs.

Previous large cohort studies (>30 patients) have reported the presence of at least one conventional adenoma in 69% to 85% of patients with HPS and >5 conventional adenomas in 21% to 32% of patients.<sup>22,23,28-30</sup> Concordantly, in the present study, *APC*-MCR mutations were detected in two HPS CRCs (13%). The identification of an HPS CRC (patient 11) located in a conventional adenoma of the same clonal origin, reflected by the identical *APC*-MCR mutation in both components, is significant because this proves that the classic adenoma-carcinoma pathway<sup>52</sup> is also operational in patients with HPS.

The apparent dominance of the serrated over the non-serrated CRC pathway in HPS may be due to a greater intrinsic risk of tumor progression of the serrated polyps or may be simply a reflection of the numerical prevalence of serrated polyps over adenomas. To our knowledge, the only study that has addressed this issue in two HPS CRC cases reported no *APC* mutations.<sup>23</sup> In that study, however, patients with >10 conventional adenomas were excluded. In the present study, all cases satisfied the World Health Organization criteria for HPS in which the presence or number of conventional adenomas is not an issue. In patient 11 with HPS and the classic CRC, a relative abundance of conventional adenomas was observed (12 adenomas versus 17 serrated polyps), suggesting a stochastic rather than an intrinsically biased process of carcinogenesis. In the other *APC*-MCR-mutated HPS CRC (patient 6), a *BRAF* mutation was also identified. Assuming that this CRC is of monoclonal origin, it may be the outcome of an elusive "fusion" pathway that combines mechanisms associated with both conventional adenomas and serrated polyps, as proposed previously.<sup>36</sup>

We observed four HPS CRCs with nuclear CTNNB1 staining associated with the WNT pathway. Although in these CRCs no *APC*-MCR mutations or *CTNNB1* exon 4 to 10 hotspot mutations were identified, alternative mechanisms may be operational to activate the WNT pathway, eg, methylation of the *APC* promoter regions and MSI-related frameshift mutations in WNT pathway regulators, such as *AXIN2*.<sup>53</sup> In these patients with HPS, a median of only one adenoma (range, zero to five) was identified, suggesting that the WNT pathway may, indeed, be involved at some stage of carcinogenesis via the serrated pathway. Considering that no *BRAF* mutations or directly

adjacent serrated polyps were found, it seems unlikely that these CRCs are the outcome of a proposed fusion pathway, but formally this cannot be excluded.

Based on these observations, we conclude that distinct *APC*- and non-*APC*-mediated CRC pathways are functional in HPS. A serrated pathway, skewed toward initial *BRAF* mutations and proximal localization, however, seems to predominate, most likely owing to the numerical prevalence of serrated polyps in these patients. From this finding it is inferred that all polyp types in HPS should be considered clinically relevant and should be removed.

## References

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Ehemann C, Anderson R, Ajani UA, Kohler B, Edwards BK: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J Natl Cancer Inst* 2008, 100:1672-1694
2. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. *Cell* 1990, 61:759-767
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988, 319:525-532
4. Hawkins NJ, Ward RL: Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. *J Natl Cancer Inst* 2001, 93:1307-1313
5. Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y, Watanabe H: DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? *J Clin Pathol* 1999, 52:5-9
6. Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, Leggett BA: Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. *J Clin Pathol* 1999, 52:455-460
7. Jass JR, Iino H, Ruzskiewicz A, Painter D, Solomon MJ, Koorey DJ, Cohn D, Furlong KL, Walsh MD, Palazzo J, Edmonston TB, Fishel R, Young J, Leggett BA: Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. *Gut* 2000, 47:43-49
8. Jass JR, Young J, Leggett BA: Hyperplastic polyps and DNA microsatellite unstable cancers of the colorectum. *Histopathology* 2000, 37:295-301
9. Jass JR: Serrated route to colorectal cancer: back street or super highway? *J Pathol* 2001, 193:283-285
10. Makinen MJ, George SM, Jernvall P, Makela J, Vihko P, Karttunen TJ: Colorectal carcinoma associated with serrated adenoma: prevalence, histological features, and prognosis. *J Pathol* 2001, 193:286-294
11. Yao T, Nishiyama K, Oya M, Kouzuki T, Kajiwara M, Tsuneyoshi M: Multiple "serrated adenocarcinomas" of the colon with a cell lineage common to metaplastic polyp and serrated adenoma: case report of a new subtype of colonic adenocarcinoma with gastric differentiation. *J Pathol* 2000, 190:444-449
12. Jass JR: Serrated adenoma of the colorectum and the DNA-methylator phenotype. *Nat Clin Pract Oncol* 2005, 2:398-405
13. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass JR, Leggett BA: *BRAF* mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut* 2004, 53:1137-1144
14. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD, Barker MA, Arnold S, Simms LA, Leggett BA, Young J, Jass JR: Promoter hypermethylation frequency and *BRAF* mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. *Fam Cancer* 2004, 3:101-107
15. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: *rAF/RAS* oncogenes and mismatch-repair status. *Nature* 2002, 418:934
16. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R, Searle



- J, McKeone D, Fraser L, Purdie DR, Podger K, Price R, Buttenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR: Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. *Am J Pathol* 2001, 159:2107–2116
17. Azimuddin K, Stasik JJ, Khubchandani IT, Rosen L, Riether RD, Scarlato M: Hyperplastic polyps: "more than meets the eye"? report of sixteen cases. *Dis Colon Rectum* 2000, 43:1309–1313
18. Warner AS, Glick ME, Fogt F: Multiple large hyperplastic polyps of the colon coincident with adenocarcinoma. *Am J Gastroenterol* 1994, 89:123–125
19. Urbanski SJ, Kossakowska AE, Marcon N, Bruce WR: Mixed hyperplastic adenomatous polyps: an underdiagnosed entity: report of a case of adenocarcinoma arising within a mixed hyperplastic adenomatous polyp. *Am J Surg Pathol* 1984, 8:551–556
20. Goldstein NS, Bhanot P, Odish E, Hunter S: Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. *Am J Clin Pathol* 2003, 119:778–796
21. Boparai KS, Dekker E, van ES, Polak MM, Bartelsman JF, Mathus-Vliegen EM, Keller JJ, van Noesel CJ: Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology* 2008, 135:2014–2018
22. Chow E, Lipton L, Lynch E, D'Souza R, Aragona C, Hodgkin L, Brown G, Winship I, Barker M, Buchanan D, Cowie S, Nasioulas S, du SD, Young J, Leggett B, Jass J, Macrae F: Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. *Gastroenterology* 2006, 131:30–39
23. Carvajal-Carmona L, Howarth K, Lockett M, Polanco-Echeverry G, Volikos E, Gorman M, Barclay E, Martin L, Jones A, Saunders B, Guenther T, Donaldson A, Paterson J, Frayling I, Novelli M, Phillips R, Thomas H, Silver A, Atkin W, Tomlinson I: Molecular classification and genetic pathways in hyperplastic polyposis syndrome. *J Pathol* 2007, 212:378–385
24. Hyman NH, Anderson P, Blasyk H: Hyperplastic polyposis and the risk of colorectal cancer. *Dis Colon Rectum* 2004, 47:2101–2104
25. Rashid A, Houlihan PS, Booker S, Petersen GM, Giardiello FM, Hamilton SR: Phenotypic and molecular characteristics of hyperplastic polyposis. *Gastroenterology* 2000, 119:323–332
26. Rubio CA, Stemme S, Jaramillo E, Lindblom A: Hyperplastic polyposis coli syndrome and colorectal carcinoma. *Endoscopy* 2006, 38:266–270
27. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Tomino Y, Oda J, Mizutani M, Takayanagi S, Kishi D, Shinohara T, Yamada K, Matumoto J, Imamura K: Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. *Dig Dis Sci* 2009, 54:906–909
28. Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van LM, van Noesel CJ, Houben M, Cats A, van Hest LP, Fockens P, Dekker E: Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. *Gut* 2010, 59:1094–1100
29. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, Gattas M, Walsh MD, Clendenning M, McKeone D, Walters R, Roberts A, Young A, Hampel H, Hopper JL, Goldblatt J, George J, Suthers GK, Phillips K, Young GP, Chow E, Parry S, Woodall S, Tucker K, Muir A, Field M, Greening S, Gallinger S, Green J, Woods MO, Spaetgens R, de la Chapelle A, Macrae F, Walker NI, Jass JR, Young JP: Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. *Int J Colorectal Dis* 2010, 25:703–712
30. Burt RW, Jass J: Hyperplastic polyposis. *World Health Organisation Classification of Tumours: Pathology and Genetics*. Edited by SR Hamilton, LA Aaltonen. Berlin, Springer-Verlag, 2000, pp 135–136
31. Khalid O, Radaideh S, Cummings OW, O'Brien MJ, Goldblum JR, Rex DK: Reinterpretation of histology of proximal colon polyps called hyperplastic in 2001. *World J Gastroenterol* 2009, 15:3767–3770
32. Sandmeier D, Seelentag W, Bouzourene H: Serrated polyps of the colorectum: is sessile serrated adenoma distinguishable from hyperplastic polyp in a daily practice? *Virchows Arch* 2007, 450:613–618
33. Sandmeier D, Benhattar J, Martin P, Bouzourene H: Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. *Histopathology* 2009, 55:206–213
34. Wong NA, Hunt LP, Novelli MR, Shepherd NA, Warren BF: Observer agreement in the diagnosis of serrated polyps of the large bowel. *Histopathology* 2009, 55:63–66
35. Hamilton SR, Vogelstein B, Kudo S, et al. *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System*. Lyon, France, IARC Press, 2000, pp 104–119
36. Jass JR, Baker K, Zlobec I, Higuchi T, Barker M, Buchanan D, Young J: Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a "fusion" pathway to colorectal cancer. *Histopathology* 2006, 49:121–131
37. Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP: Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. *Am J Clin Pathol* 2005, 124:380–391
38. de Leng WW, Keller JJ, Luiten S, Musler AR, Jansen M, Baas AF, de Rooij FW, Gille JJ, Menko FH, Offerhaus GJ, Weterman MA: STRAD in Peutz-Jeghers syndrome and sporadic cancers. *J Clin Pathol* 2005, 58:1091–1095
39. de Leng WW, Westerman AM, Weterman MA, de Rooij FW, Dekken HH, De Goeij AF, Gruber SB, Wilson JH, Offerhaus GJ, Giardiello FM, Keller JJ: Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. *Clin Cancer Res* 2003, 9:3065–3072
40. Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, Hamilton SR, Rashid A: BRAF mutations in aberrant crypt foci and hyperplastic polyposis. *Am J Pathol* 2005, 166:1069–1075
41. Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A: Concordant CpG island methylation in hyperplastic polyposis. *Am J Pathol* 2002, 160:529–536
42. Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, Hamilton SR, Rashid A: BRAF mutations in aberrant crypt foci and hyperplastic polyposis. *Am J Pathol* 2005, 166:1069–1075
43. Chan TL, Zhao W, Leung SY, Yuen ST: BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. *Cancer Res* 2003, 63:4878–4881
44. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruzskiewicz AR, Barker M, Buchanan D, Young J, Jass JR: Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. *Gut* 2006, 55:1467–1474
45. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. *Cancer Res* 2005, 65:6063–6069
46. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. *Cancer Res* 2008, 68:8541–8546
47. Ogino S, Noshio K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS: CpG island methylator phenotype, microsatellite instability: BRAF mutation and clinical outcome in colon cancer. *Gut* 2009, 58:90–96
48. de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF, van den Brandt PA, de Bruine AP, van Engeland M: MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. *Ann Oncol* 2009, 20:1216–1222
49. Noshio K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S: A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. *Gastroenterology* 2009, 137:1609–1620
50. Makinen JM, Makinen MJ, Karttunen TJ: Serrated adenocarcinoma of the rectum associated with perianal Paget's disease: a case report. *Histopathology* 2002, 41:177–179
51. Makinen MJ: Colorectal serrated adenocarcinoma. *Histopathology* 2007, 50:131–150
52. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988, 319:525–532
53. Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO, Lothe RA: Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. *Neoplasia* 2005, 7:99–108